Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

Inclusion Criteria:

• Patient is able to provide written informed consent before beginning any study relatedprocedures

• Patient has a documented clinical diagnosis of major depressive disorder

• Patient is able to understand and comply with the requirements of the study, as judgedby a study investigator

Exclusion Criteria:

• Patients with a history of non-compliance as judged by the study investigator

• Patients with a known lack of response to previous treatment with quetiapine

• Patients who have participated in a clinical trial within 4 weeks of randomization